Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12877475 | 1.00 | SF3B3 (0.77) | SF3B3HMGCR | |
| SCHEMBL25436816 | 0.93 | SF3B3 (0.72) | SF3B3HMGCR | |
| SCHEMBL25436815 | 0.93 | SF3B3 (0.72) | SF3B3HMGCR | |
| SCHEMBL16181180 | 0.91 | SF3B3 (0.70) | SF3B3HMGCR | |
| SCHEMBL13503195 | 0.91 | SF3B3 (0.68) | SF3B3HMGCR | |
| SCHEMBL12877481 | 0.91 | SF3B3 (0.76) | SF3B3HMGCR | |
| SCHEMBL12833666 | 0.91 | SF3B3 (0.71) | SF3B3HMGCR | |
| SCHEMBL905749 | 0.91 | SF3B3 (0.76) | SF3B3HMGCR | |
| SCHEMBL12877318 | 0.91 | SF3B3 (0.76) | SF3B3HMGCR | |
| SCHEMBL14539614 | 0.91 | SF3B3 (0.76) | SF3B3HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100086931-A1 | METHOD FOR ASSAYING ACTION OF ANTITUMOR AGENT USING DECREASE IN GENE EXPRESSION LEVEL AS INDEX | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-08 | — | — | US | claimed |
| US-7655442-B2 | Efficiently producing a macrolide compound, in which a cyclodextrin is made to be present in a culture broth of actinomycetes; antitumor agents | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-02 | — | — | US | claimed |
| US-20100021918-A1 | METHOD FOR ASSAYING ACTION OF ANTITUMOR AGENT USING SPLICING DEFECTS AS INDEX | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-01-28 | — | — | US | claimed |
| EP-2136209-A1 | METHOD FOR EXAMINATION OF ACTION OF ANTI-CANCER AGENT UTILIZING SPLICING DEFECT AS MEASURE | Eisai R&D Management Co., Ltd. (JP) | 2009-12-23 | — | — | EP | claimed |
| EP-2131193-A1 | METHOD FOR EXAMINATION OF ACTIVITY OF ANTI-CANCER AGENT EMPLOYING REDUCTION IN EXPRESSION LEVEL OF GENE AS MEASURE | Eisai R&D Management Co., Ltd. (JP) | 2009-12-09 | — | — | EP | claimed |
| US-20070155696-A1 | Method for stabilizing macrolide compounds | MERCIAN CORPORATION (JP) | 2007-07-05 | — | — | US | claimed |
| EP-1710244-A1 | METHOD OF STABILIZING MACROLIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2006-10-11 | — | — | EP | claimed |
| US-20100086931-A1 | METHOD FOR ASSAYING ACTION OF ANTITUMOR AGENT USING DECREASE IN GENE EXPRESSION LEVEL AS INDEX | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-08 | — | — | US | disclosed |
| US-7667052-B2 | Bioactive substance | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-7667052-B2 | Bioactive substance | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-7655442-B2 | Efficiently producing a macrolide compound, in which a cyclodextrin is made to be present in a culture broth of actinomycetes; antitumor agents | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-02 | — | — | US | disclosed |
| US-20100021918-A1 | METHOD FOR ASSAYING ACTION OF ANTITUMOR AGENT USING SPLICING DEFECTS AS INDEX | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-2136209-A1 | METHOD FOR EXAMINATION OF ACTION OF ANTI-CANCER AGENT UTILIZING SPLICING DEFECT AS MEASURE | Eisai R&D Management Co., Ltd. (JP) | 2009-12-23 | — | — | EP | disclosed |
| EP-2131193-A1 | METHOD FOR EXAMINATION OF ACTIVITY OF ANTI-CANCER AGENT EMPLOYING REDUCTION IN EXPRESSION LEVEL OF GENE AS MEASURE | Eisai R&D Management Co., Ltd. (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-20090227795-A1 | TARGET MOLECULES OF PLADIENOLIDES, COMPOUNDS BINDING TO SUCH TARGET MOLECULES, AND SCREENING METHOD THEREOF | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227795-A1 | TARGET MOLECULES OF PLADIENOLIDES, COMPOUNDS BINDING TO SUCH TARGET MOLECULES, AND SCREENING METHOD THEREOF | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| EP-2053393-A1 | PLADIENOLIDE TARGET MOLECULE, COMPOUND CAPABLE OF BINDING TO THE TARGET MOLECULE, AND SCREENING METHOD FOR THE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-04-29 | — | — | EP | disclosed |
| US-20070155696-A1 | Method for stabilizing macrolide compounds | MERCIAN CORPORATION (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1710244-A1 | METHOD OF STABILIZING MACROLIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2006-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155696-A1 | Method for stabilizing macrolide compounds | MRPL21, ERG28, RPN1 | SF3B3 2845/4885HMGCR 173/4885 |
| US-20100021918-A1 | METHOD FOR ASSAYING ACTION OF ANTITUMOR AGENT USING SPLICING DEFECTS AS INDEX | RBM17, SF3B5, RBM22 | SF3B3 6/4885HMGCR 3141/4885 |
| US-20090227795-A1 | TARGET MOLECULES OF PLADIENOLIDES, COMPOUNDS BINDING TO SUCH TARGET MOLECULES, AND SCREENING METHOD THEREOF | SF3B3, SF3B2, SF3B1 | SF3B3 1/4885HMGCR 2428/4885 |
| US-20100086931-A1 | METHOD FOR ASSAYING ACTION OF ANTITUMOR AGENT USING DECREASE IN GENE EXPRESSION LEVEL AS INDEX | PLAAT5, MKI67, PLAAT3 | SF3B3 2035/4885HMGCR 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.